Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service

LaVoieHealthScience Announces Building Company Narrative Workshop at 2023 BIO International Convention


LaVoieHealthScience (LHS), an award-winning global health science investor relations and public relations consulting agency focused on advancing health and science innovations, today announced the presentation at this year's BIO International Convention entitled, "Building Your Narrative: How to Tell Your Company Story in Just 15 Slide Topics." This talk will be based on LHS' trademarked processes of creating corporate narratives and presentation decks delivered in just fifteen slide topics. President and CEO Donna LaVoie will deliver this live presentation including real-life stories and slide examples on building a company narrative tailored to your target audience including investors, business partners, media, or other stakeholders. The examples are based on LHS' trademarked methodologies, The LHS Fifteen-Slide Presentation® and LHS Immersion®.

"As I prepare to present this workshop for the 15th consecutive year, developing key message pillars to engage target stakeholders is more important than ever given the challenges in today's marketplace and the competition to differentiate companies and their products and technologies. Building your story is more than just data; it's about developing an investable story, developing terminology, and aligning messaging with your target audiences. In an unprecedented time when M&A and strategic partnering is increasingly prominent, attending this workshop will set you up for success," said Donna L. LaVoie.

The BIO International Convention will be held on June 5-8 in Boston and is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.

LaVoieHealthScience has worked with BIO to develop a thought leadership series of videos on public speaking covering The LHS Fifteen-Slide Presentation®, Public Speaking Strategies for the CEO, and Creating Your Elevator Pitch. More information on this series can be found on BIO's Company Presentation Best Practices found here.

About LaVoieHealthScience (LHS)

LHS partners with global medical and health companies and brands to build recognition and value, attract capital, and reach medical audiences, customers, and talent through integrated communications and marketing. The firm provides health science public relations and investor relations programs with strategic communications embedded into each program, designed to properly position, create visibility, and drive value. LHS has received over 60 awards in recognition of the work it has done for its clients.

Our clients are emerging and established industry leaders. LaVoieHealthScience is an INC. 5000 Hall of Fame private company, is ranked by O'Dwyer's PR as one of the leading independent healthcare PR firms in the U.S., and has an established track record of case studies and client success.


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: